Statin therapy of calcific aortic stenosis: hype or hope?

被引:27
作者
Liebe, V [1 ]
Brueckmann, M [1 ]
Borggrefe, M [1 ]
Kaden, JJ [1 ]
机构
[1] Univ Hosp Mannheim, Dept Med Cardiol 1, D-68167 Mannheim, Germany
关键词
aortic valve stenosis; calcification; inflammation; HMG-CoA reductase inhibitors; risk factors; atherosclerosis;
D O I
10.1093/eurheartj/ehi697
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Calcific aortic stenosis, with a prevalence of 3-9%, is the most frequent heart valve disease and the main cause for valve replacement in patients over 60 years of age. Once thought to be caused by a passive calcium precipitate within the aortic valve leaflets, there is now increasing evidence that development and progression of calcific aortic valve disease may be triggered by underlying genetic and cardiovascular risk factors, and is regulated by an active cellular process involving inflammatory pathways. Targeted drug therapy to prevent the progression of calcific aortic valve disease should ideally be based on the knowledge of risk factors and the molecular pathogenesis of the disease. Conflicting data exists on the potency of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (i.e. statins) to influence both risk factors and inflammatory pathways by lowering lipid levels and exerting anti-inflammatory properties, respectively. In this review, various aspects of the molecular pathogenesis of calcific aortic stenosis will be summarized and connected with recent experimental and clinical studies that address the potential benefit of the targeted drug therapy by statins in order to prevent the progression of the disease.
引用
收藏
页码:773 / 778
页数:6
相关论文
共 75 条
[41]   Effect of hydroxymethylglutaryl coenzyme A reductase inhibitors on the progression of calcific aortic stenosis [J].
Novaro, GM ;
Tiong, IY ;
Pearce, GL ;
Lauer, MS ;
Sprecher, DL ;
Griffin, BP .
CIRCULATION, 2001, 104 (18) :2205-2209
[42]   OSTEOPONTIN IS EXPRESSED IN HUMAN AORTIC VALVULAR LESIONS [J].
OBRIEN, KD ;
KUUSISTO, J ;
REICHENBACH, DD ;
FERGUSON, M ;
GIACHELLI, C ;
ALPERS, CE ;
OTTO, CM .
CIRCULATION, 1995, 92 (08) :2163-2168
[43]   ACCUMULATION OF T-LYMPHOCYTES AND EXPRESSION OF INTERLEUKIN-2 RECEPTORS IN NONRHEUMATIC STENOTIC AORTIC VALVES [J].
OLSSON, M ;
DALSGAARD, CJ ;
HAEGERSTRAND, A ;
ROSENQVIST, M ;
RYDEN, L ;
NILSSON, J .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) :1162-1170
[44]   Atorvastatin reduces NF-κB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells [J].
Ortego, M ;
Bustos, C ;
Hernández-Presa, MA ;
Tuñón, J ;
Díaz, C ;
Hernández, G ;
Egido, J .
ATHEROSCLEROSIS, 1999, 147 (02) :253-261
[45]   The amount of calcium-deficient hexagonal hydroxyapatite in aortic valves is influenced by gender and associated with genetic polymorphisms in patients with severe calcific aortic stenosis [J].
Ortlepp, JR ;
Schmitz, F ;
Mevissen, V ;
Weiss, S ;
Huster, J ;
Dronskowski, R ;
Langebartels, G ;
Autschbach, R ;
Zerres, K ;
Weber, C ;
Hanrath, P ;
Hoffmann, R .
EUROPEAN HEART JOURNAL, 2004, 25 (06) :514-522
[46]   The vitamin D receptor genotype predisposes to the development of calcific aortic valve stenosis [J].
Ortlepp, JR ;
Hoffmann, R ;
Ohme, F ;
Lauscher, J ;
Bleckmann, F ;
Hanrath, P .
HEART, 2001, 85 (06) :635-638
[47]   CHARACTERIZATION OF THE EARLY LESION OF DEGENERATIVE VALVULAR AORTIC-STENOSIS - HISTOLOGICAL AND IMMUNOHISTOCHEMICAL STUDIES [J].
OTTO, CM ;
KUUSISTO, J ;
REICHENBACH, DD ;
GOWN, AM ;
OBRIEN, KD .
CIRCULATION, 1994, 90 (02) :844-853
[48]  
Pate Gordon E., 2003, Journal of Cardiovascular Pharmacology and Therapeutics, V8, P201, DOI 10.1177/107424840300800305
[49]  
PEDERSEN TR, 1994, LANCET, V344, P1383
[50]   Progression of aortic valve calcification -: Association with coronary atherosclerosis and cardiovascular risk factors [J].
Pohle, K ;
Mäffert, R ;
Ropers, D ;
Moshage, W ;
Stilianakis, N ;
Daniel, WG ;
Achenbach, S .
CIRCULATION, 2001, 104 (16) :1927-1932